Shenyang Sunshine Pharmaceutical
Subsidiary of 3SBio Inc. (1530)
Assets
(5 total)
5Total Assets
0Approved
3Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FLT3Small molecule | Acute Myeloid Leukemia | |
| Phase 3 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease | |
| Phase 3 | PD-1 + VEGFMultispecific antibody | Non-Small Cell Lung CancerColorectal CancerEndometrial Cancer | |
| Phase 2 | PD-1 and PD-L1Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (7)
October 2027 (1)
PF-08634404Phase 1/2Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms …
Est. primary completion 2027-10-18 · NCT07227012 · CT.gov ↗
What to watch
November 2027 (3)
Est. primary completion 2027-11 · NCT07874984 · CT.gov ↗
What to watch
PF-08634404Phase 1/2Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma …
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
Est. primary completion 2027-11-30 · NCT05586074 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
PF-08634404Phase 2Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung …
Est. primary completion 2028-03-24 · NCT07476287 · CT.gov ↗
What to watch
July 2028 (1)
PF-08634404Phase 2Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease …
Est. primary completion 2028-07-29 · NCT07489066 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
PF-08634404Phase 3Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) …
Est. primary completion 2029-02-27 · NCT07222566 · CT.gov ↗
What to watch
March 2029 (1)
PF-08634404Phase 1/2Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Est. primary completion 2029-03-08 · NCT07227298 · CT.gov ↗
What to watch
June 2029 (1)
Est. primary completion 2029-06-01 · NCT07578649 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
PF-08634404Phase 3Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases …
Est. primary completion 2030-02-23 · NCT07222800 · CT.gov ↗
What to watch
June 2030 (1)
Est. primary completion 2030-06-14 · NCT07226999 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
PF-08634404Phase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer …
Est. primary completion 2031-07-22 · NCT07392892 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.